Long-acting exendin-4 and use thereof
AssigneeIndustry-Academic Cooperation Foundation Gyeongsang National University
InventorsGu Seob Roh, Meong Cheol Shin, Jong Youl Lee, Taehoon Park
Life of this patent
Estimating the term…
Abstract
The present invention relates to a long-acting exendin-4 in which an albumin binding domain (ABD) and an anti-FcRn affibody are fused to exendin-4, and a use thereof. A long-acting exendin-4 according to the present invention has an in vivo half-life that is significantly increased over that of exendin-4, which is conventionally used as an agent for treating diabetes, and resultantly acts as a diabetes therapeutic agent, which is a conventional use of exendin-4, and also exhibits both an effect of treating other metabolic diseases and diabetes complications, such as obesity and fatty liver, and an effect of alleviating cognitive impairment caused by metabolic diseases.
Claims6
A long-acting exendin-4, wherein an albumin-binding domain (ABD) and an anti-FcRn affibody are fused to exendin-4, wherein the exendin-4 is encoded by the nucleic acid sequence of SEQ ID NO:
- 4, the albumin-binding domain is encoded by the nucleic acid sequence of SEQ ID NO:
- 5, and the anti-FcRn affibody is encoded by the nucleic acid sequence of SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.